Vol. 18/No. 19 | OncologyLive

Novel Alkylating Agent Defies Mechanisms of Resistance in GBM Tumors

October 11, 2017

VAL-083, a novel alkylating agent that has demonstrated potency against brain tumor cells and can overcome resistance associated with methylguanine methyltransferase (MGMT), is being investigated in patients with glioblastoma multiforme or gliosarcoma who had progressive disease during or after treatment with bevacizumab.

Novel Approach Reduces Treatment Toxicities in Patients With HPV-Related Oropharyngeal Cancer

October 05, 2017

The incidence of mouth and throat cancer is on the rise due to transmission of the human papilloma virus, but physicians at Memorial Sloan Kettering Cancer Center have managed to significantly reduce the intensity of treatment and improve quality of life for these patients.

Debating the True Benefit of Adjuvant TKIs in High-Risk RCC

October 04, 2017

Adjuvant therapy with tyrosine kinase inhibitors for patients with high-risk renal cell carcinoma (RCC) who have undergone a nephrectomy may be supported by level IIa evidence from the National Comprehensive Cancer Network guidelines.

Immunotherapy Combinations Offer Hope in Glioblastoma

October 04, 2017

Immunotherapy has shown promise for treatment of glioblastoma multiforme (GBM), the most common primary brain tumor in adults with historically poor prognosis, but experts agree that combination regimens have the greatest potential to achieve durable response.

Experts Discuss Advanced Therapies in Relapsed/Refractory Multiple Myeloma

October 03, 2017

The advent of new agents and new classes of agents for treating relapsed or refractory multiple myeloma, a notably complex disease state, has stimulated efforts to identify the optimal way to sequence or combine these therapies.

Assumptions Regarding Cancer Risk Require Constant Reevaluation

October 01, 2017

Oncologists are well aware that by the time a new antineoplastic drug or regimen first enters the pages of a traditional reference textbook, the data supporting its use, including doses, schedules, and clinical indications, may already be considerably out-of-date.